Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Thean Hsiang Tan, Francisco Vera-Badillo et al.|The Lancet Oncology|2023Cited by 195
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y. Kong, Craig Gedye, Hao‐Wen Sim et al.|BMJ Open|2022Cited by 7
RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIALBenjamin Y. Kong, Craig Gedye, Hao‐Wen Sim et al.|Neuro-Oncology|2021Cited by 0
996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14Frank Lin, D. Thomas, M. Itchins et al.|Annals of Oncology|2025Cited by 0
TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) studySubotheni Thavaneswaran, Hui Gan, Eng-Siew Koh et al.|Neuro-Oncology|2025Cited by 0